Legend’s interim CEO sees a shorter path to the next era of CAR-T

Legend’s interim CEO sees a shorter path to the next era of CAR-T is a pharma and life sciences industry update from PharmaVoice. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.

Sy Mukherjee · 2026-08-25

Alan Bash explains how Carvykti informed the company’s strategy and what its in vivo platform still needs to prove.

Source: PharmaVoice